Shirley Liu | Co-Founder and Chief Executive Officer
GV20 Therapeutics

Shirley Liu, Co-Founder and Chief Executive Officer, GV20 Therapeutics

​​​​​​​Dr. X Shirley Liu is the co-founder and CEO of GV20 Therapeutics, a clinical stage immuno-oncology drug discovery company. Dr. Liu received PhD in Biomedical Informatics and PhD minor in Computer Science from Stanford University in 2002. Before joining GV20 in 2022, She has been a Professor of Biostatistics and Computational Biology at the Department of Data Science at Dana-Farber Cancer Institute (DFCI) and Harvard University. Her research focused on algorithm development and data integration modeling for understanding cancer gene regulation, cancer epigenetics, cancer immunology, cancer drug response and resistance. She published over 250 peer-reviewed papers, mentored 25 trainees to independent faculty positions, and has an H-index of 109. Dr. Liu is a fellow of the International Society of Computational Biology (ISCB), American Institute for Medical and Biological Engineering (AIMBE), and was a Breast Cancer Research Foundation Investigator (2017-2021). She is a recipient of the Sloan Research Fellowship (2008), Weitzman Outstanding Early Career Investigator Award from the Endocrine Society (2016), ISCB Innovator Award (2020), and the Benjamin Franklin Award for Open Access in the Life Sciences (2020).

Appearances:



Festival of Biologics Day 2 @ 09:55

Using AI to unlock the hidden antibody signals in patient tumors

  • GV20 AI can map tumor infiltrating antibodies extracted from tumor RNA-seq to tumor antigens.
  • GV20 AI predicted antibodies are enriched in functional binders to the natural form of tumor antigens. 
  • GV20 AI can rank tumor targets based on the strength of their antibody signals across tumors.
last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers